Google
RAPP — RAPPORT THERAPEUTICS, INC. COMMON STOCK (Healthcare >> Biotechnology)
RAPP FAQ
What is RAPP's ROE?
RAPPORT THERAPEUTICS, INC. COMMON STOCK reports a Return on Equity (ROE) of -22.75%.
What is RAPP's dividend yield?
RAPPORT THERAPEUTICS, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is RAPP's Deepscope Quality Score?
Deepscope rates RAPP's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy RAPP?
Deepscope's AI Timing Score for RAPP is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does RAPP belong to?
RAPPORT THERAPEUTICS, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 36.10
Price
-1.39
(-3.71%)
Day Change
|
|
|---|
RAPP, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 36.10 |
| PBV / Sector |
3.75 / 4.63
|
| Earning Per Share | -2.19 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
10.33 M
GREAT
|
| Average 1W Daily Value |
8.16 M
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:09:08 |
| Symbol | RAPP |
| Name | RAPPORT THERAPEUTICS, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 47.83 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,769.60 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 99 High Street, Boston, MA, United States, 02110
Phone: 857 321 8020
Website: https://www.rapportrx.com
Employees: 84
Sector: Healthcare >> Biotechnology
Description: Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
